BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1296@pharmaconomics
DTSTAMP:20260707T041737Z
DTSTART;VALUE=DATE:20260323
DTEND;VALUE=DATE:20260324
SUMMARY:VALN Phase 3 — LB6V
DESCRIPTION:Phase 3 trial results for LB6V in Lyme disease are due Mar 23\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1836564/000162828026034662/q126resultspr.htm\n\nTrack it: https://pharmaconomics.com/e/1296
URL:https://pharmaconomics.com/e/1296
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:VALN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR